0001209191-23-050240.txt : 20230921 0001209191-23-050240.hdr.sgml : 20230921 20230921083019 ACCESSION NUMBER: 0001209191-23-050240 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230919 FILED AS OF DATE: 20230921 DATE AS OF CHANGE: 20230921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41802 FILM NUMBER: 231267795 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neumora Therapeutics, Inc. CENTRAL INDEX KEY: 0001885522 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 844367680 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (857) 760-0900 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: RBNC Therapeutics, Inc. DATE OF NAME CHANGE: 20210929 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-19 1 0001885522 Neumora Therapeutics, Inc. NMRA 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 0 1 See Remark 1 0 Common Stock 1911729 I F-Prime Capital Partners Life Sciences Fund VII LP Common Stock 2023-09-19 4 C 0 3475646 A 5387375 I F-Prime Capital Partners Life Sciences Fund VII LP Common Stock 2023-09-19 4 C 0 84965 A 5472340 I F-Prime Capital Partners Life Sciences Fund VII LP Common Stock 2023-09-19 4 C 0 63724 A 63724 I F-Prime Inc. Common Stock 2023-09-19 4 C 0 88289 A 88289 I FBRI LLC Series A-2 Preferred Stock 2023-09-19 4 C 0 63724 D Common Stock 63724 0 I F-Prime Inc. Series A-2 Preferred Stock 2023-09-19 4 C 0 3475646 D Common Stock 3475646 0 I F-Prime Capital Partners Life Sciences Fund VII LP Series B Preferred Stock 2023-09-19 4 C 0 84965 D Common Stock 84965 0 I F-Prime Capital Partners Life Sciences Fund VII LP Series A-2 Preferred Stock 2023-09-19 4 C 0 88289 D Common Stock 88289 0 I FBRI LLC On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: FBRI LLC and F-Prime Inc are wholly-owned subsidiaries of FMR LLC. F-Prime Capital Partners Life Sciences Advisors Fund VII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2023-09-21